Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI AG 2020-03-01
Reeks:International Journal of Molecular Sciences
Onderwerpen:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Online toegang:https://www.mdpi.com/1422-0067/21/7/2275
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items